US FDA Study May Proceed letter for Clarity’s Cu-64 SAR-bisPSMA trial in prostate cancer
Sydney, Australia 7 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a confirmation from the US Food and Drug Administration (FDA) that the diagnostic 64Cu SAR-bisPSMA trial (COBRA) may proceed. Clarity’s Executive Chairman, Dr…